P
BFK
vs
F
FTSE Straits Times Singapore
Over the past 12 months, BFK has underperformed FTSE Straits Times Singapore, delivering a return of -40% compared to the FTSE Straits Times Singapore's 0% growth.
Stocks Performance
BFK vs FTSE Straits Times Singapore
Performance Gap
BFK vs FTSE Straits Times Singapore
Performance By Year
BFK vs FTSE Straits Times Singapore
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.